NCT06049329 is a Phase 1 clinical trial of NNC0487-0111 in Obesity, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT06049329?

NCT06049329 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT06049329?

Interventions in NCT06049329: NNC0487-0111, Placebo (NNC0487-0111).

Is NCT06049329 still recruiting?

NCT06049329 is currently completed. Last updated 5 March 2025.

Last reviewed 2025-03-05 · How we verify

NCT06049329

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Completed Phase 1 Last updated 5 March 2025

What this trial tests

Phase 1 trial testing NNC0487-0111 in Obesity in 36 participants. Completed in 15 December 2023.

Timeline

14 September 2023

Primary endpoint
15 December 2023

15 December 2023

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	36
Start date	14 September 2023
Primary completion	15 December 2023
Estimated completion	15 December 2023
Sites	1 location across Japan

Drugs / interventions tested

NNC0487-0111 — full drug profile →
Placebo (NNC0487-0111)

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 18 to 55, male only, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as an oral tablet to Japanese participants.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.
Volčanšek Š, Koceva A, Jensterle M, Janež A, et al · · 2025 · cited 10× · PMID 40332747 · DOI 10.1007/s13300-025-01733-8
Recent achievements and future directions of anti-obesity medications.
Grandl G, Novikoff A, Liu X, Müller TD. · · 2024 · cited 10× · PMID 39582489 · DOI 10.1016/j.lanepe.2024.101100
G protein-coupled receptors and obesity.
Pocai A. · · 2023 · cited 5× · PMID 38161982 · DOI 10.3389/fendo.2023.1301017

Verify or expand the search:

Other trials of NNC0487-0111

Trials testing the same drug.

NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
NCT07503210 — AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintai · Phase 3 · not yet recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07533175 — AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type · Phase 3 · not yet recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06049329 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 5 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06049329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing